

Corrigendum

The Neural Correlates of Social Anxiety Disorder and Response to Pharmacotherapy

Clinton D Kilts, Jeffrey E Kelsey, Bettina Knight, Timothy D Ely, F DuBois Bowman, Robin E Gross, Amy Selvig, Angelita Gordon, D Jeffrey Newport and Charles B Nemeroff

Neuropsychopharmacology (2006) 31, 2254. doi:10.1038/sj.npp.1301205

Correction to: *Neuropsychopharmacology* (2006) 31, 2243–2253. doi:10.1038/sj.npp.1301053

The authors provided the following financial disclosures. Dr Nemeroff consults to, serves on the Speakers' Bureau and/or Board of Directors, has been a grant recipient, and/or owns equity in one or more of the following: Abbott Laboratories, Acadia Pharmaceuticals, AFSP, APIRE, Astra-Zeneca, BMC-JR LLC, Bristol-Myers-Squibb, CeNeRx, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Entrepreneur's Fund, Forest Laboratories, George West Mental

Health Foundation, GlaxoSmithKline, i3 DLN, Janssen Pharmaceutica, Lundbeck, NARSAD, NIMH, NFMH, NovaDel Pharma, Otsuka, Pfizer Pharmaceuticals, Quintiles, Reevax, UCB Pharma, Wyeth-Ayerst.

Dr Kilts consults to and/or serves on the Advisory Board of, and has been a grant recipient of one or more of the following: Janssen Pharmaceutica, Forest Laboratories, George West Mental Health Foundation, NIMH, NIDA, Lundbeck. Dr Kelsey is on the Speakers Bureau of: Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Wyeth and Consults with: Eli Lilly and Wyeth-Ayerst.